Clinical Trial Update: Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period [Phase 4]

View source ↗

Summary

Phase 4 study assessing side effects during regular injections of Turoctocog alfa (Factor VIII) over 8 weeks in people with Haemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder
• Haemophilia

Drugs mentioned

• Turoctocog alfa (turoctocog alfa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 4 | Status: COMPLETED | Results posted: 2020-03-18